'Focused Diversification' Will Lead to Above-Average Growth, Says Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss group plans to outpace industry growth through maintaining R&D investment across chosen areas, and through improving efficiency.
You may also be interested in...
Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.
Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.
Novartis Sales Grow at Double Digits, Helped by Generics, Vaccines
A diversified business allows the Swiss group to report a 14% sales rise for 2010, although pharma sales growth was just half that